High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

Patrick Marcellin, Hugo Cheinquer, Manuela Curescu, Geoffrey M. Dusheiko, Peter Ferenci, Andrzej Horban, Donald Jensen, Gabriella Lengyel, Alessandra Mangia, Denis Ouzan, Massimo Puoti, Maribel Rodriguez-Torres, Mitchell L. Shiffman, Manuela Schmitz, Fernando Tatsch, Mario Rizzetto

Research output: Contribution to journalArticle

Abstract

The ability to predict which patients are most likely to achieve a sustained virologic response (SVR) with peginterferon/ribavirin would be useful in optimizing treatment for hepatitis C virus (HCV). The objective of this large international noninterventional cohort study was to investigate the predictive value (PV) of a virologic response (VR) by weeks 2, 4, and 12 of treatment on SVR. Treatment-naive HCV monoinfected patients (N = 7,163) age ≥18 years were prescribed peginterferon/ribavirin at the discretion of the treating physician according to country-specific requirements in accordance with the local label. The main outcome measure was the PV of a VR (HCV RNA

Original languageEnglish
Pages (from-to)2039-2050
Number of pages12
JournalHepatology
Volume56
Issue number6
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Hepacivirus
Randomized Controlled Trials
Ribavirin
Cohort Studies
Therapeutics
Outcome Assessment (Health Care)
RNA
Physicians
Sustained Virologic Response

ASJC Scopus subject areas

  • Hepatology

Cite this

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. / Marcellin, Patrick; Cheinquer, Hugo; Curescu, Manuela; Dusheiko, Geoffrey M.; Ferenci, Peter; Horban, Andrzej; Jensen, Donald; Lengyel, Gabriella; Mangia, Alessandra; Ouzan, Denis; Puoti, Massimo; Rodriguez-Torres, Maribel; Shiffman, Mitchell L.; Schmitz, Manuela; Tatsch, Fernando; Rizzetto, Mario.

In: Hepatology, Vol. 56, No. 6, 12.2012, p. 2039-2050.

Research output: Contribution to journalArticle

Marcellin, P, Cheinquer, H, Curescu, M, Dusheiko, GM, Ferenci, P, Horban, A, Jensen, D, Lengyel, G, Mangia, A, Ouzan, D, Puoti, M, Rodriguez-Torres, M, Shiffman, ML, Schmitz, M, Tatsch, F & Rizzetto, M 2012, 'High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials', Hepatology, vol. 56, no. 6, pp. 2039-2050. https://doi.org/10.1002/hep.25892
Marcellin, Patrick ; Cheinquer, Hugo ; Curescu, Manuela ; Dusheiko, Geoffrey M. ; Ferenci, Peter ; Horban, Andrzej ; Jensen, Donald ; Lengyel, Gabriella ; Mangia, Alessandra ; Ouzan, Denis ; Puoti, Massimo ; Rodriguez-Torres, Maribel ; Shiffman, Mitchell L. ; Schmitz, Manuela ; Tatsch, Fernando ; Rizzetto, Mario. / High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. In: Hepatology. 2012 ; Vol. 56, No. 6. pp. 2039-2050.
@article{55b0afa812574a9e814f2adc7753e133,
title = "High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials",
abstract = "The ability to predict which patients are most likely to achieve a sustained virologic response (SVR) with peginterferon/ribavirin would be useful in optimizing treatment for hepatitis C virus (HCV). The objective of this large international noninterventional cohort study was to investigate the predictive value (PV) of a virologic response (VR) by weeks 2, 4, and 12 of treatment on SVR. Treatment-naive HCV monoinfected patients (N = 7,163) age ≥18 years were prescribed peginterferon/ribavirin at the discretion of the treating physician according to country-specific requirements in accordance with the local label. The main outcome measure was the PV of a VR (HCV RNA",
author = "Patrick Marcellin and Hugo Cheinquer and Manuela Curescu and Dusheiko, {Geoffrey M.} and Peter Ferenci and Andrzej Horban and Donald Jensen and Gabriella Lengyel and Alessandra Mangia and Denis Ouzan and Massimo Puoti and Maribel Rodriguez-Torres and Shiffman, {Mitchell L.} and Manuela Schmitz and Fernando Tatsch and Mario Rizzetto",
year = "2012",
month = "12",
doi = "10.1002/hep.25892",
language = "English",
volume = "56",
pages = "2039--2050",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

AU - Marcellin, Patrick

AU - Cheinquer, Hugo

AU - Curescu, Manuela

AU - Dusheiko, Geoffrey M.

AU - Ferenci, Peter

AU - Horban, Andrzej

AU - Jensen, Donald

AU - Lengyel, Gabriella

AU - Mangia, Alessandra

AU - Ouzan, Denis

AU - Puoti, Massimo

AU - Rodriguez-Torres, Maribel

AU - Shiffman, Mitchell L.

AU - Schmitz, Manuela

AU - Tatsch, Fernando

AU - Rizzetto, Mario

PY - 2012/12

Y1 - 2012/12

N2 - The ability to predict which patients are most likely to achieve a sustained virologic response (SVR) with peginterferon/ribavirin would be useful in optimizing treatment for hepatitis C virus (HCV). The objective of this large international noninterventional cohort study was to investigate the predictive value (PV) of a virologic response (VR) by weeks 2, 4, and 12 of treatment on SVR. Treatment-naive HCV monoinfected patients (N = 7,163) age ≥18 years were prescribed peginterferon/ribavirin at the discretion of the treating physician according to country-specific requirements in accordance with the local label. The main outcome measure was the PV of a VR (HCV RNA

AB - The ability to predict which patients are most likely to achieve a sustained virologic response (SVR) with peginterferon/ribavirin would be useful in optimizing treatment for hepatitis C virus (HCV). The objective of this large international noninterventional cohort study was to investigate the predictive value (PV) of a virologic response (VR) by weeks 2, 4, and 12 of treatment on SVR. Treatment-naive HCV monoinfected patients (N = 7,163) age ≥18 years were prescribed peginterferon/ribavirin at the discretion of the treating physician according to country-specific requirements in accordance with the local label. The main outcome measure was the PV of a VR (HCV RNA

UR - http://www.scopus.com/inward/record.url?scp=84870533049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870533049&partnerID=8YFLogxK

U2 - 10.1002/hep.25892

DO - 10.1002/hep.25892

M3 - Article

C2 - 22706730

AN - SCOPUS:84870533049

VL - 56

SP - 2039

EP - 2050

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -